Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Novo Nordisk Woes Weigh on Denmark's Economy. Here's How.
Published: May 20, 2025 by: Barrons
Sentiment: Negative
Denmark's economy contracted 0.5% in the first quarter of 2025, largely due to the pharmaceutical industry.
Read More
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Published: May 19, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.
Read More
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
Read More
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S' share price decline is driven by negative sentiment despite strong sales growth, profitability, and efficiency metrics. Competition from Eli Lilly and supply issues have pressured market share, but Novo Nordisk remains highly profitable with a robust financial position. Recent CEO departure and pipeline setbacks have fueled pessimism, yet ongoing investments and U.S. expansion support long-term prospects.
Read More
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.
Read More
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Published: May 16, 2025 by: New York Post
Sentiment: Negative
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has failed to impress investors.
Read More
Novo Nordisk CEO to step down, citing market challenges
Published: May 16, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss a new leadership shakeup at drug-maker Novo Nordisk.
Read More
SPX 6000 Close? Plus, NVO CEO Out, CAVA Dip and Buffett's STZ Position
Published: May 16, 2025 by: Schwab Network
Sentiment: Neutral
Kevin Green joins Morning Trade Live as markets open mixed to begin Friday's trading. For the intraday S&P 500 (SPX) ranges KG is watching, he points to 5960-5970 for upward resistance.
Read More
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Read More
Novo Nordisk Stock Suffers After C-Suite Shakeup
Published: May 16, 2025 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) is down 3.9% to trade at $63.60 this morning, after a C-suite shakeup.
Read More
Novo Nordisk CEO to step down after eight years at the helm
Published: May 16, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years leading the Danish pharmaceutical giant, known for its blockbuster obesity and diabetes drugs Wegovy and Ozempic. The company said on Friday the decision was made by mutual agreement with the company's board amid recent market challenges, including increased competition and a significant decline in the company's share price since mid-2024.
Read More
Novo Nordisk CEO to step down amid pressure from obesity drug competition
Published: May 16, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) has announced that chief executive Lars Fruergaard Jørgensen will step down after eight years in the role, as the company contends with growing pressure in the obesity treatment market. The Danish pharmaceutical group, best known for its Wegovy weight-loss drug, said Jørgensen would stay on temporarily to support a smooth leadership transition.
Read More
Talks to replace Novo Nordisk CEO lasted several weeks, board chair says
Published: May 16, 2025 by: Reuters
Sentiment: Neutral
Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ongoing for the past few weeks, the company's board Chair Helge Lund told Reuters on Friday.
Read More
Instant View: Wegovy-maker Novo Nordisk ousts CEO as competition in obesity drug market heats up
Published: May 16, 2025 by: Reuters
Sentiment: Negative
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Read More
Novo Nordisk CEO to step down as competition weighs on Wegovy maker's share price
Published: May 16, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news from Novo Nordisk.
Read More
Ozempic maker Novo Nordisk boots CEO over stock-price fall
Published: May 16, 2025 by: Market Watch
Sentiment: Negative
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday.
Read More
Novo Nordisk CEO to Step Down Amid Market Challenges
Published: May 16, 2025 by: WSJ
Sentiment: Negative
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.
Read More
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk.
Read More
Novo Nordisk's CEO to step down as competition weighs on Wegovy maker's share price
Published: May 16, 2025 by: CNBC
Sentiment: Negative
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership."
Read More
Novo Nordisk CEO to step down
Published: May 16, 2025 by: Reuters
Sentiment: Neutral
Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down.
Read More
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Read More
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
Read More
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
Published: May 14, 2025 by: Proactive Investors
Sentiment: Positive
Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and metabolic disease therapies, which include the injectables Wegovy and Ozempic.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Novo Nordisk: Is obesity wonder drug Wegovy losing its investment appeal?
Published: May 12, 2025 by: Proactive Investors
Sentiment: Neutral
Private investors considering Novo Nordisk (NYSE:NVO) should approach with measured optimism. The Danish drugmaker is a global leader in the fast-growing obesity market, but Morgan Stanley believes the near-term outlook is mixed.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
Published: May 12, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight.
Read More
Novo Nordisk Stock Is Slumping Today. Here's Why.
Published: May 12, 2025 by: Barrons
Sentiment: Negative
Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.
Read More
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug announcement caused undue panic; NVO's advanced pipeline, including oral semaglutide and Amycretin, remains highly competitive. The partnership with Hims & Hers mitigates legal risks and boosts distribution, promising significant synergies and long-term benefits for the Company.
Read More
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya® (somapacitan) was non-inferior to the once-daily growth hormone Norditropin® (somatropin) in improving yearly growth rate (as measured by height velocity [HV] at Week 52) in pre-pubertal children born small for gestational age (SGA)1, or with Noonan syndrome (NS)2, or with idiopathic short stature (ISS)3. In addition, superiority was achieved for once-weekly Sogroya® versus daily growth hormone in children with NS2, as well as compared to lower doses of daily growth hormone in children born SGA1.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406